Summit Therapeutics

SMMT

市值 US$117億

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.

Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approxi.

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer (TNBC). Datroway is a specifically engineered TROP2 directed DXd antibo.

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies i.

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant read ivonescimab correctly.

SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.

AstraZeneca Plc (NYSE:AZN) on Tuesday agreed to invest $2 billion in newly issued equity in Summit Therapeutics Inc. (NASDAQ:SMMT) to accelerate the development of ivonescimab in combination with antibody-drug conjugates (ADCs) across tumor types.

Summit Therapeutics shares surged more than 20% in pre-market trading on Tuesday after AstraZeneca agreed to invest $2 billion in the company and collaborate on a series of clinical studies involving their cancer treatments. The deal, announced late Monday, sent UK-listed shares of AstraZeneca 1.9% higher to a two-month high.

AMD was inching higher after announcing an $8.2 billion deal to buy World Labs, with other chip stocks gaining.